Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Abstract Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional similarity assessment is a key compo...

Full description

Bibliographic Details
Main Authors:	Di Cao, Chunping Deng, Guangying Wang, Xiong Mei, Jianhua Xie, Yuanmei Liu, Yujie Liu, Yili Yang, Shengfeng Li, Cuihua Liu
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-07-01
Series:	Drugs in R&D
Online Access:	https://doi.org/10.1007/s40268-023-00432-8

Similar Items

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study
by: Likun Chen, et al.
Published: (2023-11-01)

Exposure–response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024-01-01)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
by: B. Miguel‐Lillo, et al.
Published: (2023-12-01)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
by: Zhiting Zhao, et al.
Published: (2023-01-01)

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
by: Daniil L. Stroyakovskiy, et al.
Published: (2022-02-01)

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
by: Alireza Lashay, et al.
Published: (2020-08-01)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
by: Ahmad Mirshahi, et al.
Published: (2021-01-01)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
by: Ran Jin, et al.
Published: (2023-06-01)

Physicochemical stability study of a biosimilar of Bevacizumab in vials and after dilution in 0.9% NaCl in polyolefin intravenous bags
by: Vieillard Victoire, et al.
Published: (2023-03-01)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
by: Jin Wang, et al.
Published: (2019-08-01)

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
by: Martin Demarchi, et al.
Published: (2021-01-01)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
by: Mark A. Socinski, et al.
Published: (2021-11-01)

In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma
by: Georgina A. Cardama, et al.
Published: (2023-08-01)

A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
by: C. Schwabe, et al.
Published: (2023-04-01)

Intravitreal bevacizumab
by: Bakulesh M Khamar
Published: (2018-01-01)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015-12-01)

Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)
by: Chakraborty S, et al.
Published: (2024-01-01)

Validation of a Size-Exclusion Chromatography Method for Bevacizumab Quantitation in Pharmaceutical Preparations: Application in a Biosimilar Study
by: Alexis Oliva, et al.
Published: (2019-09-01)

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
by: Zhuo Ye, et al.
Published: (2015-08-01)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022-02-01)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
by: Yijia Jiang, et al.
Published: (2023-08-01)

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-01-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-06-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
by: Muñoz-Villegas P, et al.
Published: (2021-05-01)

Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment
by: Ping Liu
Published: (2012-04-01)

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
by: Greg Cantin, et al.
Published: (2023-10-01)

Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
by: Yujie LIU, et al.
Published: (2019-02-01)

Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
by: Xinyi Xu, et al.
Published: (2022-07-01)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
by: Marie Mayenga, et al.
Published: (2023-07-01)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01)

The influence of bevacizumab on platelet function
by: M Fehr, et al.
Published: (2011-07-01)

Efficiency of subconjunctival bevacizumab on pterygium
by: Alenka Lavrič, et al.
Published: (2012-06-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

BEVACIZUMAB FOR RETINAL VEIN OCCLUSION
by: Andrea Radotma Silitonga, et al.
Published: (2020-02-01)

Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021-07-01)

Lasting Controversy on Ranibizumab and Bevacizumab
by: Lihui Zou, Huiying Lai, Qi Zhou, Fei Xiao
Published: (2011-01-01)

Analysis on Bevacizumab with PDT for CSC
by: Min Yang, et al.
Published: (2018-05-01)